Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
CDTX Stock Chart & Stats
$220.19
-$4.82(-17.85%)
At close: 4:00 PM EST
$220.19
-$4.82(-17.85%)
Day’s Range― - ―
52-Week Range$15.22 - $221.20
Previous CloseN/A
Volume155.01K
Average Volume (3M)1.78M
Market Cap
$6.93B
Enterprise Value$2.15B
Total Cash (Recent Filing)$293.65M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Mar 11, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding31,439,371
10 Day Avg. Volume939,648
30 Day Avg. Volume1,776,729
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.05
Price to Sales (P/S)133.87
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.78
Enterprise Value/Ebitda-11.32
Forecast
1Y Price Target
$209.67Price Target Upside-4.78% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-7.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsMerck announced a proposed acquisition of Cidara Therapeutics, which is expected to be beneficial for the company.
Market PotentialCDTX estimates the market for its flu prophylaxis could be a 100 million plus total addressable market in the U.S.
Regulatory AdvancesThe FDA granted Breakthrough Therapy designation to CD388, which highlights its potential and medical need.
Bears Say
Acquisition RisksThe rating is downgraded to Neutral from Buy due to potential risks such as the acquisition not being completed.
Milestone Delivery ConcernsFactors that could impede the current rating include not delivering on clinical milestones that could delay or prevent payment from Merck.
Rating DowngradeThe rating on CDTX shares is downgraded to Equal-weight from Overweight.
Cidara Therapeutics News
CDTX FAQ
What was Cidara Therapeutics’s price range in the past 12 months?
Cidara Therapeutics lowest stock price was $15.22 and its highest was $221.20 in the past 12 months.
What is Cidara Therapeutics’s market cap?
Cidara Therapeutics’s market cap is $6.93B.
When is Cidara Therapeutics’s upcoming earnings report date?
Cidara Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 89 days.
How were Cidara Therapeutics’s earnings last quarter?
Cidara Therapeutics released its earnings results on Nov 06, 2025. The company reported -$3.1 earnings per share for the quarter, missing the consensus estimate of -$1.337 by -$1.763.
Is Cidara Therapeutics overvalued?
According to Wall Street analysts Cidara Therapeutics’s price is currently Overvalued.
Does Cidara Therapeutics pay dividends?
Cidara Therapeutics does not currently pay dividends.
What is Cidara Therapeutics’s EPS estimate?
Cidara Therapeutics’s EPS estimate is -1.58.
How many shares outstanding does Cidara Therapeutics have?
Cidara Therapeutics has 31,439,371 shares outstanding.
What happened to Cidara Therapeutics’s price movement after its last earnings report?
Cidara Therapeutics reported an EPS of -$3.1 in its last earnings report, missing expectations of -$1.337. Following the earnings report the stock price went up 5.829%.
Which hedge fund is a major shareholder of Cidara Therapeutics?
Currently, no hedge funds are holding shares in CDTX
Cidara Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$209.67 (-4.78% Downside)
$209.67 (-4.78% Downside)
Blogger Sentiment
Bullish
CDTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 698.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.3%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
909.12%
12-Months-Change
Fundamentals
Return on Equity
-68.70%
Trailing 12-Months
Asset Growth
219.50%
Trailing 12-Months
Company Description
Cidara Therapeutics
Cidara Therapeutics (CDTX) is a biopharmaceutical company focused on the development of innovative therapies to treat serious fungal infections and other diseases. The company is primarily engaged in the research and development of its lead product candidates, which include novel antifungal agents and immunotherapies. Cidara operates in the biotechnology sector, leveraging advanced scientific approaches to create targeted treatments that address significant unmet medical needs in infectious diseases.
CDTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the development and funding of CD388, along with strong financial positioning. However, there are challenges related to manufacturing scale-up and uncertainties in flu vaccination rates and study enrollment timing.View all CDTX earnings summariesCDTX Stock 12 Month Forecast
Average Price Target
$209.67
▼(-4.78% Downside)
Technical Analysis
Catalyst Pharma
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
Ownership Overview
Currently, No data available
---